Chester County News and Community Website
WILMINGTON, DE — Incyte has selected eight healthcare professionals and researchers from major U.S. cancer centers for its 2026 MPN Heroes program, recognizing contributions to clinical research, treatment access and …
Incyte Recognizes Eight Specialists in Rare Blood Cancer Care Read More WILMINGTON, DE — Incyte Corporation (Nasdaq: INCY) will release its third-quarter 2026 financial results on October 29, providing investors with an update on the biopharmaceutical company’s performance across its hematology, …
Incyte Sets October 29 Date for Third-Quarter Earnings Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) won U.S. approval for zilurgisertib, a treatment it developed for fibrodysplasia ossificans progressiva, giving the company a regulatory milestone and a transferable priority-review voucher …
Incyte Wins FDA Approval for Rare Bone Disease Drug Read More WILMINGTON, DE — Incyte Corporation (Nasdaq: INCY) granted equity awards covering 39,728 shares to 24 new employees on Aug. 3, using its shareholder-approved inducement plan to support recruitment across the …
Incyte Uses Equity Awards to Recruit 24 Employees Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) secured European Commission approval for Opzelura cream to treat moderate atopic dermatitis in certain adults, giving the Wilmington-based drugmaker a second European indication for …
Incyte Wins EU Approval for Opzelura in Atopic Dermatitis Read More WILMINGTON, DE — Incyte raised its 2026 sales guidance after second-quarter revenue climbed 38% to $1.67 billion, though a $246 million noncash accounting benefit tied to an agreement with federal …
Incyte Raises 2026 Outlook as Sales Surge on CMS Benefit Read More WILMINGTON, DE — Incyte Corp. (Nasdaq: INCY) will present early clinical data on two cancer treatments that have advanced into Phase 3 testing at the ESMO Congress in Madrid this …
Incyte Advances Two Cancer Drugs as ESMO Congress Nears Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported that its experimental drug latarcibart reduced the median annualized bleeding rate by 81% in a 16-patient Phase 1/2 study, supporting the company’s decision …
Incyte Drug Cuts Bleeding Rate 81% in Early VWD Study Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) will release its second-quarter 2026 financial results on July 28 before U.S. markets open, with executives scheduled to discuss the results during an investor …
Incyte Sets July 28 Earnings Call as Investors Await Results Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has completed its $1.25 billion acquisition of Vega Therapeutics, adding a Phase 3 treatment candidate for von Willebrand disease to its late-stage hematology pipeline …
Incyte Closes $1.25 Billion Vega Deal to Expand Hematology Pipeline Read More